L-DOS47 / Helix BioPharma 
Welcome,         Profile    Billing    Logout  
 8 Diseases   1 Trial   1 Trial   71 News 
  • ||||||||||  L-DOS47 / Helix BioPharma
    Enrollment closed, Enrollment change, Trial completion date, Metastases:  L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer (clinicaltrials.gov) -  Oct 31, 2024   
    P1/2,  N=28, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=20 --> 28 | Trial completion date: Aug 2025 --> Nov 2024
  • ||||||||||  L-DOS47 / Helix BioPharma
    Trial termination, Combination therapy, Metastases:  A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC (clinicaltrials.gov) -  Jun 2, 2024   
    P1,  N=14, Terminated, 
    Recruiting --> Active, not recruiting | N=20 --> 28 | Trial completion date: Aug 2025 --> Nov 2024 Completed --> Terminated; Slow enrolment - standard of care evolved over the duration of the study such that treatment regimen employed in the study was no longer current standard of care for first line resulting in recruitment challenges.
  • ||||||||||  L-DOS47 / Helix BioPharma
    Journal:  L-DOS47 Elevates Pancreatic Cancer Tumor pH and Enhances Response to Immunotherapy. (Pubmed Central) -  Feb 24, 2024   
    Using chemical exchange saturation transfer-magnetic resonance imaging (CEST-MRI) to measure the tumor extracellular pH (pHe), we confirmed that L-DOS47 raises the tumor pHe from 4 h to 96 h post injection in acidic tumors (average increase of 0.13 units). Additional studies showed that combining L-DOS47 with anti-PD1 significantly increases the efficacy of the anti-PD1 monotherapy, reducing tumor growth for up to 4 weeks.
  • ||||||||||  L-DOS47 / Helix BioPharma
    Trial completion date, Trial primary completion date, Metastases:  L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer (clinicaltrials.gov) -  Oct 4, 2023   
    P1/2,  N=20, Recruiting, 
    Additional studies showed that combining L-DOS47 with anti-PD1 significantly increases the efficacy of the anti-PD1 monotherapy, reducing tumor growth for up to 4 weeks. Trial completion date: Aug 2023 --> Aug 2025 | Trial primary completion date: Aug 2023 --> Aug 2024
  • ||||||||||  L-DOS47 / Helix BioPharma
    Trial completion date, Trial primary completion date, Metastases:  L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer (clinicaltrials.gov) -  Mar 17, 2022   
    P1/2,  N=20, Recruiting, 
    No Trial completion date: Oct 2021 --> Aug 2023 | Trial primary completion date: Oct 2021 --> Aug 2023
  • ||||||||||  L-DOS47 / Helix BioPharma
    Enrollment change, Trial termination, Combination therapy:  A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma (clinicaltrials.gov) -  Aug 25, 2021   
    P2,  N=9, Terminated, 
    N=136 --> 9 | Suspended --> Terminated; Study was halted at this time due to other budgetary priorities. Completion of reporting has been delayed first due to covid restrictions and more recently due to war in Ukraine.
  • ||||||||||  L-DOS47 / Helix BioPharma
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC (clinicaltrials.gov) -  Feb 24, 2020   
    P1,  N=14, Completed, 
    Research Funding: Helix BioPharma Corp. Recruiting --> Completed | N=40 --> 14 | Trial completion date: Oct 2020 --> Sep 2019 | Trial primary completion date: Oct 2020 --> Aug 2019
  • ||||||||||  L-DOS47 / Helix BioPharma
    LDOS 47 (STARLIGHT BALLROOM) -  Feb 21, 2020 - Abstract #IASLCLCTT2020IASLC_LCTT_326;    
  • ||||||||||  L-DOS47 / Helix BioPharma
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC (clinicaltrials.gov) -  Mar 14, 2019   
    P1,  N=40, Recruiting, 
    Recruiting --> Completed | N=40 --> 14 | Trial completion date: Oct 2020 --> Sep 2019 | Trial primary completion date: Oct 2020 --> Aug 2019 Trial completion date: Dec 2018 --> Oct 2020 | Trial primary completion date: Jun 2018 --> Oct 2020
  • ||||||||||  L-DOS47 / Helix BioPharma
    Enrollment closed, Enrollment change, Trial primary completion date, Monotherapy:  A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 (clinicaltrials.gov) -  Aug 15, 2017   
    P1/2,  N=76, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=60 --> 76 | Trial primary completion date: Apr 2017 --> Oct 2017
  • ||||||||||  L-DOS47 / Helix BioPharma
    Trial primary completion date, Combination therapy, Metastases:  A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC (clinicaltrials.gov) -  Aug 14, 2017   
    P1,  N=40, Recruiting, 
    Recruiting --> Active, not recruiting | N=60 --> 76 | Trial primary completion date: Apr 2017 --> Oct 2017 Trial primary completion date: Jun 2017 --> Jun 2018
  • ||||||||||  L-DOS47 / Helix BioPharma
    Trial primary completion date, Combination therapy, Metastases:  A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC (clinicaltrials.gov) -  Mar 21, 2017   
    P1,  N=40, Recruiting, 
    Trial primary completion date: Dec 2016 --> Apr 2017 Trial primary completion date: Dec 2016 --> Jun 2017
  • ||||||||||  L-DOS47 / Helix BioPharma
    Enrollment open, Trial primary completion date, Combination therapy, Metastases:  A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC (clinicaltrials.gov) -  Feb 22, 2016   
    P1,  N=40, Recruiting, 
    Trial primary completion date: Mar 2016 --> Dec 2016 Active, not recruiting --> Recruiting | Trial primary completion date: Mar 2016 --> Dec 2016